ARMP
Armata Pharmaceuticals·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
High Gross Profit Margin
Significant Net Income Decline
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARMP
Armata Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company focusing on targeted phage therapy for antibiotic-resistant infections
5005 McConnell Avenue, Los Angeles, CA 90066
--
Armata Pharmaceuticals, Inc., was established under Washington state law in March 1989 as a wholly-owned subsidiary of Immunex Corporation and began operations in 1992 as an independent targeted genetics company. The company is a clinical-stage biotechnology company focused on developing pathogen-specific phage therapies for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary phage-based technologies.
Company Financials
EPS
ARMP has released its 2025 Q3 earnings. EPS was reported at -0.74, versus the expected -0.42, missing expectations. The chart below visualizes how ARMP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARMP has released its 2025 Q3 earnings report, with revenue of 1.16M, reflecting a YoY change of -61.02%, and net profit of -26.68M, showing a YoY change of -386.68%. The Sankey diagram below clearly presents ARMP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
